Lead optimisation
Hit to lead
Assay Development
Therapeutic area
  • Inflammation

What the technology does

A humanised monoclonal antibody against the IL-25 receptor IL-17BR that shows activity in models of lung fibrosis, colitis and asthma


Affinities of <1nM, desirable biophysical properties for a therapeutic drug, potential for therapeutic benefits in multiple diseases involving type 2 immune responses

Main application field



Therapeutic – antibody


Lead optimisation

Intellectual Property

Patents granted in Japan (JP20120504066T), United States (US20130056559), Australia (AU20100233535), Europe (EP20100712110), China (CN201080022541) and Hong Kong (HK20120111452). Published in Canada (CA20102757104) and India (IN2011DN08006).


Collaboration or exclusive licence

Key Contact

  • In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. A backup of your data will be held but only authorised individuals will be able to access your data. If you would like your data to be removed, please email
    Please see our Privacy policy in relation to the personal data you submit to us through this page.
  • We would love to send you information about LifeArc news and events. Please let us know if you would like us to contact you by selecting one of the following options:
All Licensing Opportunities